Lexicon Announces Telotristat Etiprate Data To Be Presented At North American Neuroendocrine Tumor Society Annual Symposium

Lexicon Pharmaceuticals, Inc.

today announced that data from the TELESTAR Phase 3 clinical study of telotristat etiprate has been accepted for presentation at the North American Neuroendocrine Tumor Society annual symposium to be held from October 15-17, in Austin, Texas. In addition, data from interviews with patients who completed the randomized treatment portion of the TELESTAR study will be presented for the first time in a poster session. Telotristat etiprate, which has received Fast Track and Orphan Drug designation from the U.S. Food and Drug Administration, is in development for the treatment of carcinoid syndrome in cancer patients whose symptoms are not adequately controlled by long-acting somatostatin analog therapy, the current standard of care. The oral presentation, entitled "Results of TELESTAR: A Phase 3, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate in Patients with Carcinoid Syndrome Not Adequately Controlled by Somatostatin Analog," will be presented at the Clinical Science Symposium at 8:30 a.m. CDT, on October 16, by primary investigator, Matthew H. Kulke, M.D., Director, Program in Neuroendocrine and Carcinoid Tumors and Senior Physician, Dana Farber Cancer Institute, and Associate Professor of Medicine, Harvard Medical School. The poster, entitled "Assessing Treatment Benefit of Telotristat Etiprate in Patients with Carcinoid Syndrome: Patient Exit Interviews," will be presented during the poster session at 6 p.m. CDT, on October 16.